From ASH Meeting on Hematologic Malignancies: What is the prognosis for symptomatic, bulky FL that has returned after R-CHOP?

Director of the James P. Wilmot Cancer Institute and director of Hematologic Malignancies Clinical Research at the University of Rochester Medical Center in Rochester, New York

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the meeting via an audience response system, but we want to know what you would do. Send in your responses for a chance to win an ASH Clinical News-themed prize!

CLINICAL DILEMMA

A 58-year-old woman was diagnosed with symptomatic, bulky follicular lymphoma with a mesenteric mass measuring 10 cm. She was treated with R-CHOP for six cycles and achieved complete remission. She was then started on rituximab maintenance as per the PRIMA schedule.

One year later, on a scheduled visit for maintenance, she self-identified a growing axillary node. On biopsy, this was found to again be grade 1 follicular lymphoma, similar in appearance to her previous sites of disease. There was no evidence of transformation.

Which of the following is true regarding this presentation?

  1. Adding obinutuzumab to bendamustine confers a survival benefit.
  2. Her 5-year overall survival is 65 percent.
  3. The combination of lenalidomide and rituximab is approved for this indication.
  4. Her long-term prognosis remains favorable since there is no evidence of transformation, and FL-IPI score at diagnosis was intermediate.

Here’s how MHM audience members and ASH Clinical News readers responded:

MHM Audience Responses

  • Adding obinutuzumab to bendamustine confers a survival benefit
  • Her 5-year overall survival is 65%
  • Lenalidomide and rituximab is approved for this indication
  • Her long-term prognosis remains favorable

ASH Clinical News Reader Responses

  • Adding obinutuzumab to bendamustine confers a survival benefit
  • Her 5-year overall survival is 65%
  • Lenalidomide and rituximab is approved for this indication
  • Her long-term prognosis remains favorable

Disclaimer: ASH does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this article is solely at your own risk.

SHARE